NEUCA Full Year 2024 Earnings: EPS: zł34.54 (vs zł33.30 in FY 2023)

NEUCA (WSE:NEU) Full Year 2024 Results

Key Financial Results

• Revenue: zł12.6b (up 6.8% from FY 2023).
• Net income: zł154.2m (up 5.5% from FY 2023).
• Profit margin: 1.2% (in line with FY 2023).
• EPS: zł34.54 (up from zł33.30 in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

NEUCA Earnings Insights

Looking ahead, revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Healthcare industry in Europe.

Performance of the market in Poland.

The company's shares are down 7.1% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of NEUCA's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.